LRP5-related primary osteoporosis

LRP5-related primary osteoporosis is a rare inherited bone disease caused by changes (mutations) in the LRP5 gene. LRP5 stands for Low-Density Lipoprotein Receptor-Related Protein 5. This gene plays a key role in controlling how much bone your body builds and maintains. When the LRP5 gene does not work properly, the body cannot build strong, dense bones, leading to a condition called primary osteoporosis — meaning the bone loss is caused directly by the gene change, not by aging, diet, or other medical conditions. People with this condition have bones that are weaker than normal and break much more easily than expected. Fractures can happen from minor bumps or falls that would not normally cause a break. The spine, hips, and wrists are commonly affected. Some people also experience back pain, loss of height, and a stooped posture over time. Symptoms can begin in childhood or early adulthood, which is unusual for osteoporosis, a condition most people associate with older age. Treatment focuses on strengthening bones and preventing fractures. Doctors may use medications called bisphosphonates (such as alendronate or zoledronic acid) or other bone-building drugs to slow bone loss. A newer medication called romosozumab, which targets the same biological pathway as LRP5, has shown promise. Regular monitoring with bone density scans (DEXA scans), calcium and vitamin D supplementation, and fall prevention strategies are all important parts of care. While there is currently no cure, early diagnosis and treatment can significantly reduce the risk of serious fractures and improve quality of life.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Bring these to your next appointment

• Q1.What type of LRP5 mutation do I have, and what does that mean for how severe my condition might be?,Should my parents, siblings, or children be tested for the same gene change?,Which bone-strengthening medication is best for my age and situation, and what are the risks?,How often should I have bone density scans, and what numbers should I be aiming for?,Are there any activities or sports I should avoid to protect my bones?,Is romosozumab or any newer treatment an option for me given my LRP5 mutation?,Are there any clinical trials I could join to access new treatments?

Common questions about LRP5-related primary osteoporosis